Purpose

The proposed protocol is a 3 group double-blind, placebo-controlled outpatient study of the safety and efficacy of Adderall-XR (ER-MAS) in the treatment of comorbid ADHD and cocaine dependence. Since this medication has independently shown promise in helping with ADHD and cocaine abuse, we are proposing that it may be successful in the treatment of comorbid ADHD and cocaine abuse. We plan to enroll 75 subjects in a 14-week trial. The primary objectives of the study are to determine the efficacy of ER-MAS in promoting cocaine abstinence and improvement in ADHD symptomology among cocaine-dependent patients with comorbid ADHD.

Type of Study: Clinical Trial
Setting of Study: outpatient
Clinical Trials.gov number: NCT00553319
Providing Clinical Treatment?: Yes
No Cost Treatment?: Yes
Care is provided in languages: English

Study Activities

Filling Out Forms
Computer Tasks
Blood Samples
Psychophysiology measurements
Provides Payment: Reimbursement for transportation
Provides Payment: Compensation for study related procedures

Eligibility

Ages Eligible for Study: 18 Years - 65 Years
Genders Eligible for Study: Both
This study is not recruiting Healthy Volunteers.

Criteria

Location: 513 WEST 166TH STREET 3RD FLOOR NEW YORK, NY 10032
Clinic: Substance Treatment and Research Services
Division: Substance Abuse

Study chairs or principal investigators:
Frances Rudnick Levin M.D., Principal Investigator

Co-investigators:
John Mariani,
Adam Bisaga,